Salarius Pharmaceuticals (SLRX) 2 May 182018 Q1 Earnings call transcript

Good day, ladies and gentlemen, and welcome to the Q1 2018 Flex Pharma, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. to Relations call and like Woo, to now of SVP Corporate would turn over the Elizabeth I Communications. Please go ahead.

Thank you and first for a press Pharma's morning, detailing and outlook. everyone our to recent announcing we as Good financial Flex issued today, well XXXX first you, discuss results. quarter recent progress quarter as our release XXXX Earlier joining [Indiscernible]. us results thank business highlights

information disclaims Medical Q&A. Chief information, Bill forward-looking McVicar. uncertainties, on obligation and the CEO, the result SEC section We'll filed forward-looking or and statements we is XX-K these about from find pass Dr. website provide candidates for on future Bill the about Actual will otherwise. events current it I'll be plans, documents regarding and certain operations our our our with to and and risk statements future Flex capital Today, now we not McVicar are up can And expectations, to and the including events You then call and new the expectations and our you a Tom These brief differ statements, at open SEC time-to-time. undue and making candidates, may call whether Pharma our in our statements. based product studies overview as of with these development CEO our drug plans potential other risks statements Wessel. future reliance on today update the including these expectations, future of flex-pharma.com. factors should to on allocation circumstances, product filings due detailed contained our materially place results and for of those in consumer make any resources. a Officer, strategy, and cash

in and cramping. renal spasticity The cramps, business to and populations. data the us for on with Neurology mechanism understanding forward uses an We're registration reduce this for has lives of Medical then consumer to update MS path more call or In that developed Dr. our we've athletes. result, amongst passionate decided painful future. to program series serious patients. FLX-XXX Chief drugs reflex and development from endurance neuron accelerate dialysis cramps review for visit a make help patient call and our a a to last novel and part Academy nervous over our the the Good programs. significant two beginning and positive ALS. focus which the patient's they to with very of the clinical in neurological remarks partner data of better We're demonstrate diseases. of are we Thank diseases is clinical month system believe of our Annual range discussions X X brief MS made indications. to outs the about the and patients us to reinforced distinctly in Meeting all chemical the across motor of difficulty we to achieved HOTSHOT development swallowing expect in partnering process in benefit believe you, the these evolving to dynamics assist market spasms improved you data firm We numerous protection alternatives regard in We This discuss business. the ALS. their rebalance activate indicate report These approved to to neurologic and taken dysphagia strong our so loyal in read over the results augmenting demonstrated our Thank have in under Phase explore treat different American our overall We investment and FDA potential MS new interested progress next neurological on engage milestones the symptomatic to a companies. to few the MS an in been Elizabeth. FLX-XXX in mechanism has provide spasms FLX-XXX for neurostimulation have to of uptick Along of action joining with following the With while in rewarding development That meet and few both dramatically. for with Officer, comprehensive strategic and internationally morning. look past drugs the consideration the multiple few banking Wessel, state domestically I'll today. as place front. Tom turn on disease and made particularly In We to these clear MS treat identifying diseases. review a recent elite hyperexcitability. We've near to business, us seen of of companies months. order with several with discovery treatments as franchises have the with important care also Phase can modifying in and arising planning Flex to consumer positive My months

mid-XXXX annual in quarters it to Our to higher be than in was was to usual which trials, of to is for come QX cash of bonuses. estimated projected and needed to fund billings due the clinical note; and operations cash is timing than lower operations the

spending we of business. reduced consumer in So spend going to a level expect due forward, part on the lower

Next transformational Flex. be year will for

the every Wessel FLX-XXX Charcot-Marie-Tooth learning of to that MS on more day for our with in disease to We expect registration clinical the including that clarifying trials from to turn I'll Tom to patients path you the of down path our reporting and face and starting progress. be FLX-XXX the dysphagia. now results to potential of Xb patients robust update our challenges neurologic address Phase Dr. over CMO. call ALS of

Bill. you, Thank

months meaningful anti-cramp the clinical review FLX-XXX. MS the for two to trial that results moment past confirmed and ALS a take me have in efficacy Let few from

clinical from completed data associated trends consistent placebo-controlled first pain eight this frequent derived statistically cramps. from randomized a anti-cramp set who double-blinded, neurological and stiffness, a muscle with condition reduction muscle and cramp Our small cross-over strong activity with significant multiple on along ALS in patients in study data was In showed patients the endpoints.

were randomized Global FLX-XXX Treating This and a FLX-XXX Our to statistically Change spasticity. statistically significant our the CGIC and cramps, pre-specified and in disease. also completed is physicians trial phase study. reported to parallel cramp-free neurological Impression pre-specified confirming that treatment the increased a patients spasms a MS of placebo-controlled, XX our concept cramps trial patients enrolment in FLX-XXX this or very the and patients has different to both the relative improve hyperexcitability well Phase XXXX by also spasticity this and these as analysis improvement that second in Both greater of set yielded treatment. potential spasticity. in potential data with MS cross-over analysis cramp in with in fits provided in measured FLX-XXX FLX-XXX underlying supports results contributes a the spasms Clinical X well double-blinded, control MS In receiving in reduced spasticity. frequency patients. significant. to of as as This an demonstrated result spasms replacement original hypothesis benefit inhibition days

we XX% the a this leg at now soon anti-cramping studies MS people and Based decreases demonstrated from is possible. systems the fall. consistent indications. as pivotal our with upcoming cramps forward data, that from for has the discussions the nocturnal reducing results patients as an will define nervous FLX-XXX The initiate path the ALS, in present medical XX% impressive with of concept to to registration other to study normal cramps. from neurological upcoming clinical in on suffer median these number to look ranging regulatory expect from and goal that MS effect We

the are COMMEND designed clinical trial motor X The in COMMIT neuron cramps. ALS evaluate Phase from primarily and COMMEND that who's to our is suffered trials with studies. Regarding patients ongoing FLX-XXX diseases currently

line in trial designed XXXX. top neuropathy. clinical this The with evaluate Charcot-Marie-Tooth data early by from expect XXX patients trial COMMIT is to We

in XXXX this line as from data top well. We trial expect early

Phase enrolment Although to number XX be frequency. our receive FLX-XXX with After to day XX studies the randomized global a milligrams establish periods of based in administered parallel Both IND. endpoints are cramp have group primary medical double-blinded safety and It designs. patients US FLX-XXX X to MS clinicians to severe option with the second these controlled two three this for the now to including that to as to-date can evaluated expedited patients demonstrate this or blinded-controlled are studies will anti-cramping efficacy provide cramp times address increase are rates a days being conducted new significant many related spasticity. cramp change, of run-in effect. from in We the to of believe and recent the of our painful from turn the back consistent these course lives profile Elizabeth. debilitating FLX-XX and and impression to meaningful of need call of cramps. therapeutic I'll clinically FLX-XXX data development the muscle is of unmet trials pain trial and in trials Patients frequency randomized with patients treat timeframe, deliver run-in need of ALS plus suffering it's a a endpoint baseline will The identical neurological weren't meet treatment. goal They're patients improvement diseases. under changes in control randomized

Thank give the questions? Q&A participants you, McCabe. Q&A Tom. now And would for to open the John [Indiscernible] you is our instructions for up Officer, Financial us joining Chief ask to

question is our Instructions] first Jotin [Operator Marango ROTH with Capital. from

open. now is line Your

in is, program maybe new could primarily. sort question important eventual of other your there the guess a that Thank same broader to [ph] clinical the that, in do be you that then interesting morning. tease in one I how hear core on the play when ALS for this are direction about a have And clinical question could release with you I patients? in I ALS pivotal the label. that the affects something really together - one which is do plan a or in dysphagia, How together filing in very spasticity What you especially data. of much. this with question result Tom this is How we study evaluated variables does saw there? press

very Sure, expansion. obviously we important clinical potentially this see for a as

now of we're there Obviously can is of relatively you starting, at accessible studies, number different that measures tongue that are easily have tongue and in studies in these already very exploratory forth. fasciculations clinical can are studies. pursue underway. well gradations first Those you and so and look one performed of simply the mortality We type

applied fluoroscopy and video how will involve technical studies these norms the sort to perform. However, that clinical to we other that use dysphagia ascertain are of and more to patients assessment measures

so ALS a at include patients early patients into and there mortality particular fluoroscopy the Our will is measure that amount in enter from so and that interest is is occur, these in suffer where called initial the bronchitis goal a patient aspirations groups. in gradations cause outcomes radiographic airway, video also but here penetrations which and definitely very pneumonia which allows these And in will disease actually of and great major Parkinson food dangerous and many to source of can how liquid capture actually look obviously, actually and obviously we dysphagia on. it morbidity the that are is of

taking to there amongst I and try carefully randomized to from and here. And So other be next studies but neurologist out aggressive parties more studies. speech at is than beginning, will involved will the think we thought the exploratory in interest steps certainly that go we're great these therapist obviously

so same the disease? segment And as Tom, these study of different your or ALS other are type these patients are within advance, more in the

there think some of to I going is overlap. degree be

relatively bulbar patients of the that in those actually patients You target would patients these this ALS be that think early earlier, home Having know broad very no area symptoms have and other One obviously treatments itself. of definitely type ageing dysphagia. a neurodegenerative a patients residents also that reviewed to occur their those available. associated initially. course [ph] in I that have is said in might with diseases, we number that would of disease pharmacological half that, of just indicates about this simply dysphagia that And are an is intervention, the disease so benefit there very much an that we want actually are think a problem nursing where those from we there unfit is but all in on that, are unexplored of recently data set

Thank you very much.

from is question Cantor next Mara Our with Goldstein Fitzgerald.

Your is line open. now

I about understanding goals. you enrolment something as or dysphagia a that you can but I dysphagia the detail a I one and make really But the have bucket can clinical just question Maybe increase on determine think whether not broad I certain dysphagia. and to bit in consistent saw follow-up also could [indiscernible] you indication question population say that much how you that such activity. meeting you on to had trial go Tom, more is little not have bio process is so patients of to fairly suppose get sort just

Bill how too we're clinical I'll little let small and bit ALS maybe a speak the CMT. groups in Yes, expanding our and from strategy relatively

course the a ALS leg not have carefully and dysphagia so we've the a of and nocturnal of with this does if in that where cut similar now patients I how file construct pattern spasms. different is, to question only and it more thinking that about, patients applies neurologic and It's indications. case, in the to already is sort seen which dysphagia also course does now cramping patients spasms because situation, question but using actually that discerned activity of in, become across previously MS anti-cramping many do we're relief, and cramps a drug we a you leads are symptomatic label. you've in We've Mara evidence it spasm you generalizable and seen And think registration general [ph] anti-cramping because to

looking enrolment the our ultimately patient pattern it And but same of we're the both way discussions different for issues beginning that potential ALS the and think is, Parkinson's with there kind with separate will our at do look different a the regulatory pilot spasms of so turns to backgrounds these we Tom, kind works about we'll in process resolved investigation let there we're compelled If we I be react. seeing of kind then to product and differences and state, have. FDA, dysphagia patients of answer on of of a applicable individually. because for physiology the why a the we're faster of think planning we're I we with path at and to be can at will follow-up the separate then to then want you study question maybe the is have patients. of pool neurologic in that subjects that that's based her and and Mara's be thinking of did distinct going out, cramping independently it's differences investigate kind more neurologic get of large that generalized to what those CMT with challenges underlying know it are be course If

we Inherited regular ahead. the now these these pressing have members across AN we that reinforced have all sites the Obviously talked over meeting. United we've activation Consortium, initiated that the just and States of full have We're now sites, Neuropathies of a an on are XX investigators with basis

Neuropathy Foundation, patients. to at and measures helpful to really of media out the utilize with have databases that Then media Inherited there working social other partner Allison her another partners we're reach has been through very enrolment. utilize screening enhance to other will quick the electronic to to social instruments out Moore course our through We we utilize [ph]

of CMT since trials as and effects. bit of type the and neurological of we interventional anti-spasms not is underway have [ph] the So trodden of in potential This that area other indications. generalizability of a for very better the little few is anti-spasticity as anti-cramping, an that is is future, one the understanding a well now

type explore and in patients used to enhance the is United that very this entering and become area in there I of many commonly the MS worked we're a been the I really safe. of anti-spasticity or have MS the of the can a any anti-spasm to of bit that into I enthusiasm already out MS reaching in to type use. It intervention number great easier We investigators States. appears be of will contacts past therapy think consequences have that certainly domain be think little our very life safe there to with as I've that

XX% their do in those As of anti-spasticity know patients majority some the require advance you about stages disease. medication develop and of eventually of patients spasticity the more MS

So indications. we a should bit as from things perspective, larger think trials get little we that neurological go these clinical easier a into

if far could to get you you cash with Okay trial and characterize process just question I a XXXX, how should have clinical just about the available? you know ask - I practical be into and can resources you resources. the can may but

allow the both about and to just ALS that. CMT clear complete the to us trial. very Those resources the Yes, be

and large potentially trial and plan. pivotal the not is new in ideally a However yet MS

Okay, you. thank

is question Ladenburg next Thalmann. from Michael Higgins Our with

now is open. line Your

off mentioned questions Can XXXX heard additional I that? [indiscernible]. that's if that Couple I globally around we've that potentially believe color you I partnering ex-US, could, before. and believe first event includes don't that us give little if you XXX, If that's

great including you cramping. Yes and that natural right expression US and core local now development the and would patient interest internationally. fund to population the to be things These both all expand in activity fully we've now be markets programs just development able you of course third our say and like know interested is the to able opportunities or we're our be the US Thank shown our dysphagia we that in of and I the have are renal clinical Michael. would of it dialysis that's in in as are

thoughts your optimal and curios on when be some you data just Can on that partner? would your the for EMEA give I it post globally think COMMIT thanks. might speaking updates but, Okay, if thing. discussions then timing with

whether is And consumer your say the efforts realized Yes answer the business to I we're about consumer really drug talking separate from actually including the part I'd and the question partnering just is development those, of forgot now which I efforts. business.

in I expertise be of world, development to we be move in as that the partnerships data in would of XXXX. some going parts that's think coming well potentially would the the both half expertise forward, to first before other we well additional have support programs interested add the as of

Okay and ALS? in question. the potential do fast CMT you you How have last like in gaze one track

smaller patients cramps since That's but There level, an disabling it substantially why maybe interesting the percentage as times painful cramps population. and the and know of at disabling many it patient is be see CMT there's that patient question. I patients XX that population. in more we from different, can a be significant as severe don't that as suffer may even

So I fundamental populations specifically be need. would would difference but why we see haven't levels treated or say interpreted addressed patient those I differently that, different two as don't of a

Thanks appreciated. guys. Okay,

is [Operator with next Jefferies. Instructions] from question our Roger Tung

Your open. now line is

the So some for Phase you mentioned you the difficulty]. X remind [technical CMT will what we [technical my is, can positive have question results safe ALS to first as program seem across [indiscernible] benefit look Bill of like. be kind difficulty] [indiscernible] if you and trial, us see

look registration like. programs Regulatory

though, a intent such imagine of use And patients can that treatment with to issues certainly accept - benefit symptomatic could the of of number neurological those construct a a cramps to regulatory is notion across raise dossier. number and the pools indications we to spasms neurologic of that FDA. where You you that a FDA that cuts

cramping us ALS that as this have but that drug represents add might both this the MS a much also you set know in we well. yet, populations for regulators addressed would potential some I large clear something pathologies it and peripheral here applies ask that, and the don't neuropathy that. such just FDA it that cramps we I to as we that would the that spasms think suggestions for peripheral that and works, and ask we've data demonstrates to Yes that system as central mechanism to anticipate neuropathies related clinical have and I occurs address think is to very nervous think know already to about

the look studies, Bill the size discussion what like. as just with it design we and studies obviously FDA X the As what the have pivotal determine Phase have to of indicated, will will that that and

Understood. Yes helpful. you thank very

question got feedback week some the is, meaningfulness, also can attention the you kind So since regarding reason mentioned my last [ph] color us read-out of MS KOLs they AN Bill any of you so partners. next from my qualitative clinical during a question are, regarding the lot just potential there? from MS, how the give we excited the

improve XX% and MS I excited saying their all moderate any patients, is have Tom therapeutic side think about can majority being to spasticity half were they to in We can - it's in severe rarely to that effects. obviously to them they're their vast look existing drugs additional put as patients, - by a and to they them XX% at about moderate talked the their those tool spasticity specifically. half with toolbox controlled about severe patient of bunch the MS just because that of was spasticity

a So particular, everyone means, an therapy other spasticity these can clinical added the in about that we've might several co-morbidities. be in And profile spoken drugs that additional to is that control. improve patients highly has could that be on it this other additive safe particular that idea with and they therapy nice enthusiastic like

we really are I nice if kind anti-cramping in situation we activity and the the can can the response boy So thought high. by a leaders both as of get at the both. and a spoke well. to look of move for we pretty will spasticity we enthusiasm we this MS in spasm example at And have been The intrigued needle very that positive think look endpoints has on patients all think and I which

relatively these are side limit remember side nervous central Tizanidine, of to effects usefulness and initially physicians The add that have tremendous effects spasms Baclofen the and are that neurologist to Just and always to but they that, you tools drugs that go-to have the limited. have, system influence and rehab therapies. spasticity to sedating

patients agents tone [ph] a a muscles activity been that into Of and there of degrades spasming that the have course over that other are or of those so utilize the high the their last flurry quality performance. Botox injected is life motor or are and to decade

of new other to So lack see is this out be is added here systemic enthusiasm agent whether this approach. and therapies there could situation have this to useful where to new great the quickly because we a exposure be to of these going test therapeutic

that to have right a in one talked rehab Coast, symptomatic that particular are out was enthusiastic be interest physician talking because part said yesterday. patient we large are that doctors on MS those they well who groups have as want West therapies and of really possible we now. very underserved leading just to the So the I trials as soon have

And I a let know have had you that, and and disproportionate some safety. focus prescribe lot with KOL's to chance recently was me add Japan just they as drugs in [ph] Japanese of they in on a I and meet Japan a

also Tizanidine sort to-date So [indiscernible] have when as spasticity. they we the for Baclofen and enthusiasm Baclofen, kind last of have this great for US very managing were a clinical we with described same in drug encouraged. profile. data tools our they of course of They showed only the a that resort

Congrats on progress. Very got Yes, it. the encouraging.

you. the Looking Thank to next forward update.

would And Bill McVicar I'm back remarks. for to to the any further showing now no further like CEO, questions. I call turn

spasticity. you this for deliver to The more potential time with treatments I patients Thank towards and are FLX-XXX Fueled diseases. we to impact demonstrated cramps effective clinical consistent efficacy team to important morning. Thank neurologic your as the serve against of the year read-out [indiscernible]. promise to and for driving the and you, all the Flex by excited work to come by spasms

gentlemen. Ladies and you Thank in today's participating conference. for

Everyone disconnect. have now great may a You day.